Ranibizumab for Visual Impairment due to Diabetic Macular Edema: Real-World Evidence in the Italian Population (PRIDE Study)

Purpose. An expanded access program (PRIDE study) in Italy to provide ranibizumab 0.5 mg to diabetic macular edema (DME) patients, prior to reimbursement. Methods. Open-label, prospective, phase IIIb study. Majority of patients were not treatment-naïve before enrollment. Patients received ranibizuma...

Descripción completa

Detalles Bibliográficos
Autores principales: Menchini, Ugo, Bandello, Francesco, De Angelis, Vincenzo, Ricci, Federico, Bonavia, Luigi, Viola, Francesco, Muscianisi, Elisa, Nicolò, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532943/
https://www.ncbi.nlm.nih.gov/pubmed/26294963
http://dx.doi.org/10.1155/2015/324841

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532943/
https://www.ncbi.nlm.nih.gov/pubmed/26294963
http://dx.doi.org/10.1155/2015/324841

Ejemplares similares